Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/123876| Title: | Physicochemical and biological characterization of the TLR7 agonist SZU-106 |
| Author(s): | Herbst, Martin Kipp, Johannes Keßler, Sonja Wischke, Christian |
| Issue Date: | 2026 |
| Type: | Article |
| Language: | English |
| Abstract: | Objective Toll-like receptor 7 (TLR7) recognizes single-stranded RNA and plays a crucial role in initiating immune responses against viral pathogens. This study characterizes SZU-106, a recently developed Toll-like receptor 7 (TLR7) agonist, focusing on its physicochemical and biological properties as key determinants for assessing its suitability for drug product development. Methods Distribution coefficients (LogD) of SZU-106 were determined in silico and confirmed experimentally by the shake-flask method. Stress stability tests were performed by incubation at different pH conditions using temperatures between room temperature and 60°C. HPLC ESI–MS/MS analysis was applied to determine the main degradation products. Cytotoxicity tests with different reporter cell lines allowed excluding TRL7-mediated as well as unspecific cytotoxicity in THP-1 monocytes and macrophages. Results The analysis of distribution coefficients conducted at pH 5.6 and 7.4 confirmed the predominantly hydrophilic nature of SZU-106. Stress stability testing revealed the stability of SZU-106 in neutral aqueous solutions, while rapid degradation was noted under acidic and basic conditions with rate constants of 2.21·10–3 d-1 to 0.39 h-1. HPLC ESI–MS/MS analysis showed that SZU-106 primarily degrades via hydrolytic cleavage of its amide bonds, with four major degradation products identified and structurally characterized. Cytotoxicity assays with THP-1 monocytes and differentiated macrophages at increasing drug concentrations (10 -1000 µM) illustrated no off-target cytotoxicity and only mild, time-dependent, receptor-mediated effects in TLR7-overexpressing THP-1 cells at high SZU-106 concentrations. Conclusions This evaluation of SZU-106 supports its further development as a therapeutic TLR7 agonist, with formulation strategies representing the next stage for drug development. |
| URI: | https://opendata.uni-halle.de//handle/1981185920/125809 http://dx.doi.org/10.25673/123876 |
| Open Access: | Open access publication |
| License: | (CC BY 4.0) Creative Commons Attribution 4.0 |
| Journal Title: | Pharmaceutical research |
| Publisher: | Springer Science + Business Media B.V |
| Publisher Place: | Dordrecht [u.a.] |
| Volume: | 43 |
| Original Publication: | 10.1007/s11095-026-04031-5 |
| Page Start: | 1177 |
| Page End: | 1188 |
| Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| s11095-026-04031-5.pdf | 4.39 MB | Adobe PDF | ![]() View/Open |
Open access publication
